July 15, 2016
TD2’s VP of Nonclinical Operations, Paul Gonzales, will be presenting at the upcoming 4th Annual Tumor Models – Boston (www.tumor-models.com) on Wednesday, July 20th. The topic of the presentation is The Role of the Gut Microbiome on the Anti-Tumor Response of Immune Checkpoint Inhibitors in a Syngeneic Murine Model of HPV-Associated Cancer.
Contact us if you’re interested in a copy of the presentation.
Based on the American Cancer Society 2026 estimates and survival statistics, as of October 2026, developments in antibody-drug conjugates (ADCs), ...
Gynecologic cancers, including endometrial and ovarian cancers, remain areas of high unmet need. Advances in targeted therapy, immunotherapy, ...
CAR T-cell therapy originated in the late 1980s, first-generation constructs lacked adequate co-stimulatory signaling, causing poor CAR T-cell ...
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
© 2026 Translational Drug Development. All Rights Reserved. Terms and Conditions | Privacy Policy
